Business UpdateJun 5, 2026, 08:36 AM
Moleculin's Annamycin Shows Strong Physician Intent to Prescribe in R/R AML
AI Summary
Moleculin Biotech announced positive results from an independent market landscape assessment for its lead drug, Annamycin, in relapsed/refractory acute myeloid leukemia (R/R AML). The assessment revealed strong physician interest, with oncologists reporting a high likelihood to prescribe (6 out of 7) due to Annamycin's complete remission rates, transplant-bridging potential, biomarker-agnostic use, and reduced cardiotoxicity. Payers also showed strong support, recognizing Annamycin's potential to address a significant unmet need in the R/R AML treatment landscape.
Key Highlights
- Oncologists reported an average likelihood to prescribe Annamycin of 6 out of 7.
- Physicians cited Annamycin's complete remission rates and MRD-negative responses.
- Annamycin's potential to bridge patients to bone marrow transplant was a key advantage.
- Biomarker-agnostic applicability was viewed as highly relevant for broad patient use.
- Reduced cardiotoxicity was identified as an important differentiator, allowing repeat dosing.
- Payers indicated Annamycin's efficacy, safety, and broad applicability support value.
- Significant unmet need remains in R/R AML, especially post-venetoclax failure.
Price Impact
More from MBRX